# A Phase 3 Study of Viloxazine ER Capsules in Korean Children and Adolescents With ADHD

> **NCT07678827** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Alvogen Korea** · enrollment: 156 (estimated)

## Conditions studied

- Attention Deficit Hyperactivity Disorder
- Attention-Deficit / Hyperactivity Disorder
- ADHD

## Interventions

- **DRUG:** AK-D101
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07678827
- **Lead sponsor:** Alvogen Korea
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07
- **Primary completion:** 2027-09
- **Final completion:** 2027-09
- **Target enrollment:** 156 (ESTIMATED)
- **Last updated:** 2026-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07678827

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07678827, "A Phase 3 Study of Viloxazine ER Capsules in Korean Children and Adolescents With ADHD". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07678827. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*